Conmed (CNMD) Tops Q4 EPS by 1c; Guides
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Leerink Partners Remains Bullish as Conmed's (CNMD) Growth Acceleration Shows Evolving Turnaround
January 28, 2016 10:10 AM ESTLeerink Partners reiterated an Outperform rating on CONMED (NASDAQ: CNMD), and cut the price target to $50.00 (from $51.00), following the company's 4Q report. Results were marked by solid growth acceleration in ortho and in Leerink's view, the Surgiquest acquisition should be an important catalyst for the... More
